Sirt3 promotes hepatocellular carcinoma cells sensitivity to regorafenib through the acceleration of mitochondrial
Ruobing Wang1, Yahui Liu1, Xuguang Mi2
1Department of Hepatobiliary and Pancreatic Surgery, the First Hospital of Jilin University, Changchun, Jilin, 130021, China.
Abstract:
Regorafenib, a multiple kinase inhibitor, is recently approved for treatment of patients with advanced hepatocellular carcinoma (HCC). Previous studies demonstrated that regorafenib was a mitochondrial toxicant, which associated with the impairment of mitochondria. Sirt3 is involved in the regulation of mitochondrial function in cancers. This study aimed to investigate the mechanism of Sirt3 involved in the mitochondrial dysfunction which associated with regorafenib treatment in liver cancer cells. We found regorafenib inhibited Sirt3 and p-ERK expression in HCC cells in a dose-dependent manner. Bioinformatics analysis showed that Sirt3 expression was down-regulated in liver cancer tissues and its low expression was correlated with worse overall survival (OS) in liver cancer patients. After transfected with Sirt3 overexpression plasmid, we found that Sirt3 sensitized liver cancer cells to regorafenib and resulted in much more apoptosis with a significant increase of ROS level. However, exogenous antioxidant could not weaken the apoptosis. Mitochondrial membrane potential assay indicated that Sirt3 overexpression accelerated the mitochondrial depolarization process induced by regorafenib and aggravated mitochondrial injury. Cellular oxygen consumption assay showed that mitochondrial dysfunction was caused by the damage of the electron transport chain. The results demonstrated that Sirt3 overexpression promoted the increase of ROS and apoptosis induced by regorafenib through the acceleration of mitochondrial dysfunction by impairing function of the electron transport chain in liver cancer cells. Our studies verified the functional role of Sirt3 in regorafenib treatment and suggested that regorafenib accompanied with Sirt3 activator as a novel treatment strategy for HCC.
Insights
Regorafenib causes mitochondrial dysfunction in liver cancer cells by inhibiting Sirt3. Overexpressing Sirt3 worsens this effect, increasing cell death and suggesting Sirt3 activators could enhance regorafenib treatment for hepatocellular carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Regorafenib, a kinase inhibitor, is approved for advanced hepatocellular carcinoma (HCC).
- Regorafenib induces mitochondrial toxicity, impairing mitochondrial function.
- Sirtuin 3 (Sirt3) plays a role in regulating mitochondrial function in cancer.
Purpose of the Study:
- To investigate Sirt3's role in regorafenib-induced mitochondrial dysfunction in liver cancer cells.
- To explore the mechanism by which Sirt3 influences hepatocellular carcinoma cell response to regorafenib.
Main Methods:
- Dose-dependent analysis of regorafenib effects on Sirt3 and p-ERK expression.
- Bioinformatic analysis of Sirt3 expression in liver cancer tissues and correlation with overall survival.
- Sirt3 overexpression studies using plasmid transfection.
- Assays for apoptosis, reactive oxygen species (ROS) levels, mitochondrial membrane potential, and cellular oxygen consumption.
Main Results:
- Regorafenib inhibited Sirt3 and p-ERK expression in HCC cells.
- Low Sirt3 expression correlated with worse overall survival in liver cancer patients.
- Sirt3 overexpression sensitized HCC cells to regorafenib, increasing apoptosis and ROS levels.
- Sirt3 overexpression accelerated mitochondrial depolarization and impaired the electron transport chain, leading to mitochondrial dysfunction.
Conclusions:
- Sirt3 overexpression exacerbates regorafenib-induced mitochondrial dysfunction, ROS production, and apoptosis in liver cancer cells.
- Sirt3 plays a critical role in the cellular response to regorafenib treatment.
- Combining regorafenib with Sirt3 activators may represent a novel therapeutic strategy for HCC.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...

